External Validation Readiness

Internal Evidence, Clinical Governance, and Readiness for External Validation.

NVOX is built as a clinician-integrated, multimodal Clinical Decision Support framework for ADHD assessment. The current evidence position reflects an operationally implemented platform with a locked analytical cohort, a structured multimodal workflow, clinical governance, quality controls, and a defined roadmap for external validation.

The public evidence shows an organized internal evidence base: real-world workflow implementation, multiple assessment layers collected across completed evaluations, clinical review, clinical and medical oversight, and clear interpretation boundaries.

View Public Release v1.1

Explore Evidence Overview

External Validation Readiness

An Implemented, Governed Platform Ready for the Next Stage of External Validation

The current public evidence supports NVOX as an operationally implemented, multimodal, quality-governed clinical platform designed to organize ADHD assessment evidence and support clinician-led review.

NVOX presents its evidence position as External Validation Readiness: an operationally implemented, literature-informed, quality-governed, clinician-reviewed platform with internal operational evidence and a defined external validation roadmap.

The internal evidence base is a structured and organized foundation for the next stage: independent, protocol-driven external validation.

The current framework includes:

Operational implementation of a
structured clinical workflow

Collection and organization of multiple
information layers

Separation of evidence sources

Documentation of data quality and interpretability

Clinical review and report authorization

Clinical and medical oversight

Governance, quality controls, 
and claims boundaries

A defined roadmap for external validation

External Validation Readiness

The Public Evidence Snapshot is Based on a Locked Analytical Cohort

The Public Evidence Snapshot is Based on a
Locked Analytical Cohort

The Evidence area is designed for clinicians, informed families, institutional stakeholders, research partners, digital health reviewers, and professional readers who want to understand how NVOX is built, what currently supports the framework, and what still requires further external validation.

This section presents the clinical architecture behind NVOX, its evidence layers, claims boundaries, internal operational evidence, clinical oversight model, platform limitations, and roadmap for external validation.

Initial workflow population

1,043
Cases

Pediatric and adolescent evaluations

504
Evaluations, Ages 8 to 17

Cases excluded before final analysis

29
Cases

Final Analytical Cohort

1,014
Completed Evaluations

Adult evaluations

511
Evaluations, Ages 18 to 57

Core multimodal coverage

1,012 of 1,014
Completed Evaluations

How to read these numbers

The initial workflow population included 1,043 cases within the relevant evidence window. After a 29-case exclusion funnel, the final locked analytical cohort included 1,014 completed evaluations.

The number 1,014 is the central public denominator for this release. It represents the final cohort used for the public evidence snapshot and should be interpreted within the documented cohort window and methodological boundaries.

Core Multimodal Coverage

Nearly All Evaluations in the Final Cohort Included 
Core Multimodal Coverage.

Core multimodal coverage was achieved in 1,012 of 1,014 completed evaluations. This matters because NVOX is designed to organize a broader clinical picture rather than rely on a single score, task, or informant.

Depending on the case and pathway, multimodal coverage may include:

Structured questionnaires

Collateral input from relevant people

Existing documents

Assessment tasks

Performance measures

Digital markers

Behavioral context

Signal quality and interpretability context

Clinical review

Clinical report workflow

This is an operational measure of workflow coverage and evidence completeness.
It is not presented as a standalone diagnostic accuracy measure.

Internal Monitoring Metrics

Internal Component Metrics Help
Describe Workflow Consistency

Internal Component Metrics Help
Describe Workflow Consistency

Public Release v1.1 reports an internal dCPT workflow label alignment measure:
approximately 830 of 1,012 usable dCPT cases aligned with final workflow determinations, corresponding to approximately 82.0%, with a Wilson 95% confidence interval of 79.5% to 84.3%.

This measure helps characterize how the dCPT component behaves within the broader NVOX workflow. It is presented as internal workflow monitoring, not as independent diagnostic accuracy and not as a standalone dCPT validation result.

Its value is in showing operational consistency within the NVOX framework while preserving the correct interpretation: platform components support clinical review; they do not replace it.

Why External Validation Matters

External Validation Readiness is an 
Advanced Evidence Stage, Not an Endpoint Claim.

External Validation Readiness is an 
Advanced Evidence Stage, Not an Endpoint Claim.

NVOX has an implemented workflow, a locked cohort, an internal evidence base, clinical governance, and a roadmap for external research. The next stage is planned external validation using a defined protocol, a clear study population, an independent or semi-independent reference process, subgroup analysis, and transparent reporting.

This measure helps characterize how the dCPT component behaves within the broader NVOX workflow. It is presented as internal workflow monitoring, not as independent diagnostic accuracy and not as a standalone dCPT validation result.

Its value is in showing operational consistency within the NVOX framework while preserving the correct interpretation: platform components support clinical review; they do not replace it.

External Validation Roadmap

What the Next Stage
Should Examine

What the Next StageShould Examine

A rigorous external validation program should examine not only diagnostic agreement against an appropriate reference process, but also the broader clinical value of the assessment workflow itself.

Future validation work may include:

Full-platform external validation

External evaluation of the complete NVOX workflow against an independent or semi-independent reference process.

Profile reliability and clinical utility

Assessment of stability, usability, informant mapping, and clinical value of the structured clinical profile.

Objective task contribution

Evaluation of how performance-based assessment tasks contribute to the overall assessment workflow, while minimizing incorporation bias.

Response validity and performance authenticity

Assessment of response consistency, performance authenticity, motivation effects, coached responding, and identity assurance when relevant.

Digital marker and signal-support utility

Evaluation of the clinical contribution of digital markers and signal-support layers in the ADHD assessment context, including whether they help clinicians better understand attention, regulation, task engagement, performance consistency, and response patterns when interpreted alongside the broader clinical record.

Behavioral, oculomotor, and voice-signal robustness

Assessment of whether behavioral, oculomotor, and voice-derived signals remain stable, interpretable, and fair across device type, camera quality, lighting, glasses or occlusion, age, language, accent, audio quality, and relevant subgroups.

Access, efficiency, and underserved-population impact

Evaluation of whether NVOX can help improve access to high-quality ADHD assessment for people and families who face barriers to traditional evaluation, including cost, geographic distance, limited specialist availability, school-navigation barriers, system delays, or other access challenges.

Governance and clinical safety audit

Review of clinical governance, safety escalation, access controls, clinician override, quality controls, and lifecycle management.

Human-factors research

Study of comfort, cooperation, stress reduction, completion rates, user experience, and the role of guided remote assessment in supporting engagement.

Validation Beyond a Single Number

The Quality of an ADHD Assessment is
Not Captured by One Metric Alone

The Quality of an ADHD Assessment is Not Captured by One Metric Alone

For NVOX, validation is not limited to whether a clinician-reviewed final interpretation aligns with an external reference process. That question is important, but it is only one part of the evidence picture.

NVOX should also be evaluated for its ability to improve the quality, completeness, and usability of the assessment record itself: how information is collected, how conflicting evidence is surfaced, how clinical reasoning is supported, how clearly findings are explained, and how useful the final report is for patients, families, clinicians, and institutions.

Future validation work may include:

Clinical evidence completeness

Whether NVOX captures and organizes the information clinicians need to conduct a responsible ADHD assessment.

Clinical reasoning transparency

Whether clinicians can understand why evidence converges, diverges, or requires further interpretation.

Alternative explanations and co-occurring concerns

Whether the workflow helps surface relevant information related to sleep, anxiety, mood, learning, language, trauma, medical factors, or other co-occurring clinical concerns.

Clinician utility

Whether NVOX improves clinician confidence, documentation quality, contradiction detection, review efficiency, and clinical autonomy.

Patient and family understanding

Whether the feedback process and report help patients and families better understand the findings, functional meaning, and appropriate next steps.

Report usefulness

Whether reports are clear, functional, appropriately bounded, and useful for conversations with schools, colleges, workplaces, testing bodies, or other professionals, without presenting the report as a legal or institutional eligibility decision.

Digital marker and signal-support value

Whether NVOX digital markers and behavioral, oculomotor, and voice-related signals are stable, interpretable, fair across relevant subgroups, and clinically useful when integrated with the broader evidence record and clinician review.

Access and efficiency impact

Whether NVOX can support faster, more efficient access to high-quality ADHD assessment for people and families who may otherwise face cost, distance, availability, or system-level barriers.

Workflow quality and documented governance

Whether the review process, quality controls, access permissions, escalation pathways, clinician override, and lifecycle governance operate consistently, safely, and transparently.

Standards and Regulatory-Facing Readiness

Built to Support Professional and
Regulatory-Facing Review

Built to Support Professional and Regulatory-Facing Review

NVOX is building its evidence, governance, and documentation program to support future regulatory-facing review where appropriate, including analysis under FDA Clinical Decision Support guidance and other applicable digital health frameworks.

The public evidence release is not a certification claim, regulatory clearance document, or completed external validation report. It is a professional evidence and readiness document intended to support structured review, responsible interpretation, and future external validation planning.

Controlled Review for Qualified Reviewers

Additional Materials are Available Through a Controlled Professional Review Process

Additional Materials are Available Through a Controlled Professional Review Process

Public Release v1.1 presents a professional public version of the NVOX evidence framework. Additional technical, numerical, security, and implementation materials are not presented to the general public.

Controlled access to additional materials may be considered for qualified reviewers only, such as research institutions, academic partners, clinical or institutional reviewers, digital health technology reviewers, regulatory advisors, or similar professional review bodies, under appropriate confidentiality and review arrangements.

Institutional or Research Review Inquiry →

Want to understand the NVOX evidence position in more depth?

Start with Public Release v1.1, or continue to the Evidence pages to understand the technology, clinical review process, and governance model behind NVOX.

Explore Assessment Technology